Hiroshima University-ko ikertzaileekin lankidetzan egindako argitalpenak (1)

2024

  1. Outcomes in the Asian subgroup of the phase III randomised HIMALAYA study of tremelimumab plus durvalumab in unresectable hepatocellular carcinoma

    Journal of Hepatology